2SE Stock Chart & Stats
€0.51
€0.00(0.00%)
At close: 4:00 PM EDT
€0.51
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.37 - €0.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€47.76M
Enterprise Value€114.92
Total Cash (Recent Filing)€3.81M
Total Debt (Recent Filing)€40.11M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding78,172,035
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionThe American Medical Association has issued six new Category III Current Procedural Terminology codes for the alfapump system, paving the way for commercial adoption.
Market PotentialThe target market for alfapump could exceed $2B in the U.S.
Regulatory ApprovalThe U.S. FDA has granted Premarket Approval to alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis.
Bears Say
Market CompetitionThere is a risk of alfapump or DSR failing to achieve commercial success due to market size, penetration rate, and/or competition.
Regulatory RisksRisks include failure of DSR to secure regulatory approval in the U.S.
Sequana Medical N.V News
2SE FAQ
What was Sequana Medical N.V’s price range in the past 12 months?
Sequana Medical N.V lowest stock price was €0.37 and its highest was €0.90 in the past 12 months.
What is Sequana Medical N.V’s market cap?
Sequana Medical N.V’s market cap is €47.76M.
When is Sequana Medical N.V’s upcoming earnings report date?
Sequana Medical N.V’s upcoming earnings report date is Mar 26, 2027 which is in 177 days.
How were Sequana Medical N.V’s earnings last quarter?
Sequana Medical N.V released its earnings results on Sep 25, 2025. The company reported -€0.35 earnings per share for the quarter, missing the consensus estimate of -€0.08 by -€0.27.
Is Sequana Medical N.V overvalued?
According to Wall Street analysts Sequana Medical N.V’s price is currently Overvalued.
Does Sequana Medical N.V pay dividends?
Sequana Medical N.V does not currently pay dividends.
What is Sequana Medical N.V’s EPS estimate?
Sequana Medical N.V’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sequana Medical N.V have?
Sequana Medical N.V has 78,172,035 shares outstanding.
What happened to Sequana Medical N.V’s price movement after its last earnings report?
Sequana Medical N.V reported an EPS of -€0.35 in its last earnings report, missing expectations of -€0.08. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sequana Medical N.V?
Currently, no hedge funds are holding shares in DE:2SE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sequana Medical N.V
Sequana Medical N.V. is a medical technology company that has reached the commercial stage, dedicated to creating innovative solutions for managing excessive fluid accumulation linked to liver conditions, malignant ascites, and heart failure. The company's key offerings include the alfapump® system, an implanted device specifically designed to treat severe and resistant liver ascites as well as malignant ascites (fluid buildup caused by cancer). Additionally, it provides Direct Sodium Removal (DSR) technology to address ongoing fluid congestion in patients with heart failure. This DSR technology is integrated into the alfapump® DSR system, a fully implantable solution for direct sodium removal therapy in heart failure patients experiencing fluid overload. Established in 2006 and headquartered in Ghent, Belgium, Sequana Medical operates across Belgium, Germany, France, Switzerland, and other international regions.